Notice of Option Exercise and Termination of License Agreement for Co-Development and Co-Commercialization of Attention-Deficit/Hyperactivity Disorder Therapeutic Agents “Intuniv® Tablets 1mg/3mg” and “Vyvanse® Capsules 20mg/30mg”

-      Takeda to Solely Conduct promotional activities for Two Products from April 2023 (Scheduled)

-      Shionogi to Transfer Intuniv® Tablets 1mg/3mg and Vyvanse® Capsules 20mg/30mg Regulatory Approvals to Takeda


OSAKA, Japan, October 31, 2022 - Takeda Pharmaceutical Company Limited (Head Office: Osaka, Japan; President & CEO: Christophe Weber; hereafter "Takeda") and Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that Takeda has exercised the option right, originally granted to Shire (integrated with Takeda in 2019), to re-acquire full rights  to the attention-deficit/hyperactivity disorder therapeutic agents Intuniv® Tablets 1mg/3mg (hereafter "Intuniv®") and Vyvanse® Capsules 20mg/30mg (hereafter "Vyvanse®"), as specified in the license agreement for co-development and co-commercialization in Japan between Shire (merged with Takeda in 2019) and Shionogi, concluded in November 2011.


This option exercise by Takeda will terminate the license agreement for co-development and co-commercialization of Intuniv® and Vyvanse®. Takeda and Shionogi have concluded a basic agreement for transfer of assets, etc., based on the option exercise.


Shionogi will receive a one-time payment in fiscal 2023 to which it is entitled pursuant to the basic agreement. The license agreement for co-development and co-commercialization of Intuniv® and Vyvanse® will terminate at the end of March 2023. From April 2023, Takeda is scheduled to solely promote both products. For a period to be determined, Shionogi will continue to hold regulatory approvals for both products, and the timing of the transfer of distribution operations and the succession of regulatory approvals will be mutually agreed.


Takeda and Shionogi have been co-promoting Intuniv® and Vyvanse® for patients with attention deficit/hyperactivity disorder. The two companies will continue to work closely together for a smooth transition of the two products. In addition, both companies will continue to work to ensure stable supply of the products, provision and collection of product information, and proper use during the period until the activities are fully transferred to Takeda.




<About Attention Deficit/Hyperactivity Disorder>

Attention-deficit/hyperactivity disorder is a neurodevelopmental disorder and is also called ADHD. Symptoms include inattentiveness, hyperactivity, and impulsiveness.


<About Takeda Pharmaceutical Company Limited>

Takeda (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.


<About Shionogi & Co., Ltd.>

In its Group Vision, SHIONOGI indicates the direction in which it aims to transform itself from a drug discovery based pharmaceutical company into a HaaS* company that provides a wider array of healthcare solutions. By pursuing this mission intensively, we seek to address the healthcare needs of individuals and society on a increasingly comprehensive basis.

For more information, please visit https://www.shionogi.com/global/en/.

* Providing various healthcare services that meet customer needs in addition to providing pharmaceuticals



This media release is intended to disclose corporate information. Nothing contained in this document should be considered a solicitation, promotion, or indication for any prescription drug, including those currently under development.


For Further Information, Contact:

SHIONOGI Website Inquiry Form: https://www.shionogi.com/global/en/contact.html